Anne Bass, MD, rheumatologist at the Hospital for Special Surgery and professor of clinical medicine at Weill Cornell Medicine, discusses the potential for biosimilars to increase access to care.
TranscriptWhat role do you see biosimilars playing in increasing access to care?
Biosimliars have the potential to greatly increase access to care. Biologic agents in general have revolutionized the management of many, many rheumatic diseases, starting with infliximab in 1999, which completely changed the natural history of rheumatoid arthritis from what it was prior to the availability of [tumor necrosis factor] TNF inhibitors. Now, of course, we have a whole array of biologics that we can use. So, they’re fantastic drugs as a group, but they’re fantastically expensive— $50,000 a year and upward. And it’s going to bankrupt the system to say nothing of patients who potentially don’t have insurance access to these medications. So, the availability of biosimilars, if they are as efficacious and safe, and if– the big if– the price is low enough, there’s real potential to improve access. The problem has been that the pricing has only been 15% lower than the original drugs, which is nowhere near as low as we originally hoped, and there’s a whole variety of factors that go into that, but it’s something that we need to work on, particularly in this country. In Europe, the price differential is far greater.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.